RESEARCH TRIANGLE PARK, N.C. – March 8, 2010 – Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.
With capacity for 35 patients and healthy volunteers, the extension brings the total number of Phase I beds in London to 105 and globally to 385. This is expected to increase further in late 2010, with the opening of a Phase I unit in Hyderabad, India, initially with 50 beds, and with capacity for expansion to 100.
“Declining productivity in research and development means that the biopharmaceutical industry is under intense pressure to increase efficiency and overcome complexity,” explains Eddie Caffrey, Senior Vice President, Global Phase I at Quintiles.
“Effective early-stage development can have significant impact on speed and cost of the overall development process. Our customers need a holistic solution that combines fast and cost-efficient regulatory studies with advanced scientific expertise and techniques such as modeling and simulation, biomarkers and microdosing for more complex studies.
“With our expanded facility in London and our planned facility in Hyderabad we will be better able to provide an integrated Phase I research solution that facilitates robust decision making early.”
State-of-the-art electronic data capture and automated workflow systems link Quintiles Phase I facilities around the world, to provide harmonized data and reporting across multiple sites.
Located on the 14th floor of Guy’s Hospital in central London, the unit is adjacent to one of only five Biomedical Research Centres (BRCs) in the UK. BRC status and funding is awarded to leading NHS and University partnerships, by the government, to drive progress on innovation and translational research in biomedicine. Quintiles will work closely with experts from the BRC as appropriate, to drive forward the translation of science onto the wards -from ‘bench to bedside’.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
This press release contains “forward-looking statements,” based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include, among other things, the possibility of delays or changes in plans for our planned Hyderabad facility. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.